Blue Owl Capital Holdings’s Aquestive Therapeutics AQST Stock Holding History

Blue Owl Capital Holdings’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.92M	Sell	942,932 -405,000	-30%	-$1.7M	0.59%	28
2026 Q1	$5.59M	Buy	1,347,932 +822,932	+157%	+$3.34M	1.5%	15
2025 Q4	$3.39M	Sell	525,000 -725,000	-58%	-$4.52M	1.05%	28
2025 Q3	$6.99M	Buy	1,250,000 +330,000	+36%	+$1.43M	2.17%	16
2025 Q2	$3.05M	Hold	920,000	–	–	0.98%	25
2025 Q1	$2.67M	Buy	920,000 +20,000	+2%	+$60.5K	0.86%	29
2024 Q4	$3.2M	Sell	900,000 -325,000	-27%	-$1.5M	0.74%	27
2024 Q3	$6.1M	Buy	1,225,000 +85,000	+7%	+$331K	1.18%	21
2024 Q2	$2.96M	Buy	1,140,000 +265,000	+30%	+$885K	0.82%	25
2024 Q1	$3.73M	Buy	+875,000	New	+$2.91M	0.74%	25

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Blue Owl Capital Holdings's AQST Position: Q2 2026 in Review

Blue Owl Capital Holdings reduced its Aquestive Therapeutics (AQST) stake by 30% in Q2 2026, selling an estimated $1.7M and leaving 942,932 shares worth $3.92M. The position accounts for 0.59% of the portfolio, ranked #28.

Blue Owl Capital Holdings first reported a position in AQST in Q1 2024 and has held it in 10 quarters since. The position peaked at $6.99M in Q3 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Blue Owl Capital Holdings held 942,932 shares of Aquestive Therapeutics worth $3.92M as of Q2 2026.
Blue Owl Capital Holdings sold 405,000 Aquestive Therapeutics shares in Q2 2026, an estimated $1.7M.
Aquestive Therapeutics made up 0.59% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #28 holding.
Blue Owl Capital Holdings first reported a position in Aquestive Therapeutics in Q1 2024 and has held it in 10 quarters since.
Blue Owl Capital Holdings's Aquestive Therapeutics position peaked at $6.99M in Q3 2025.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.